1. Home
  2. ETSY vs SYRE Comparison

ETSY vs SYRE Comparison

Compare ETSY & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Etsy Inc.

ETSY

Etsy Inc.

HOLD

Current Price

$69.26

Market Cap

5.6B

ML Signal

HOLD

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

HOLD

Current Price

$69.39

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETSY
SYRE
Founded
2005
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
6.5B
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
ETSY
SYRE
Price
$69.26
$69.39
Analyst Decision
Hold
Strong Buy
Analyst Count
26
12
Target Price
$62.50
$85.08
AVG Volume (30 Days)
2.7M
804.5K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.60
N/A
Revenue
$441,231,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.44
N/A
P/E Ratio
$116.22
N/A
Revenue Growth
20.90
N/A
52 Week Low
$44.00
$13.93
52 Week High
$76.52
$78.80

Technical Indicators

Market Signals
Indicator
ETSY
SYRE
Relative Strength Index (RSI) 68.13 47.46
Support Level $67.62 $65.93
Resistance Level $70.88 $76.15
Average True Range (ATR) 2.37 3.74
MACD 0.84 -1.03
Stochastic Oscillator 91.30 32.71

Price Performance

Historical Comparison
ETSY
SYRE

About ETSY Etsy Inc.

Founded in 2005, Etsy operates a leading global marketplace, connecting roughly 87 million active buyers and 6 million sellers of unique, handmade, and vintage goods. In fiscal 2025, the firm generated $2.9 billion in revenue and almost $12 billion in gross merchandise sales. The firm monetizes its marketplace primarily through transaction fees and advertising, with core categories spanning homeware, jewelry, apparel, and craft supplies. The US drives 74% of sales, though its core geographic reach extends to the UK, Germany, Canada, and Australia.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: